首页> 外文期刊>Pharmacogenomics >CD40-1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke.
【24h】

CD40-1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke.

机译:CD40-1C> T多态性(rs1883832)与缺血性脑卒中纤维蛋白溶解后脑血管再阻塞有关。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

AIMS: To find genetic predictors of reocclusion after successful fibrinolytic therapy during the acute phase of ischemic stroke. PATIENTS & METHODS: This was a case-case prospective study analyzing 236 polymorphisms in a cohort of 222 patients treated with tissue plasminogen activator, from which 16 patients suffered a reocclusion event (7.2%). A predictive scale was generated using independent polymorphisms with a dominant/recessive model and tandem occlusion, weighted by their beta-coefficients in logistic regression. RESULTS: Using a dominant/recessive model, the rs1800801 SNP from the MGP gene (odds ratio [OR]: 15.25; 95% CI: 2.23-104.46; adjusted p = 0.006) and the rs1883832 SNP from CD40 gene (OR: 0.077; 95% CI: 0.009-0.66; adjusted p = 0.019) were independently associated with reocclusion after logistic regression adjustment by clinical predictors. In an additive model, only the rs1883832 SNP (OR: 4.43; 95% CI: 1.62-12.15; adjusted p = 0.004) was related to reocclusion occurrence. The predictive model that was generated stratified the reocclusion risk from less than 1% to more than 70%. Reocclusions were associated with neurological worsening at 24 h (patients with reocclusion: 26.7%, versus patients without reocclusion: 4.9%; p = 0.002), as it was seen for MGP -7A>G (AA: 17.2% vs AG+GG: 4.5%; p = 0.027), but not for CD40 1C>T (CC: 4.5% vs CT+TT: 7.7%; p = 0.565). There was an association between CD40 -1C>T genotype and CD40 transcriptional activity in peripheral blood mononuclear cells (median expression values TT: 65.75%, CT: 70.80%, CC: 96.00%; p = 0.023). However, CD40 soluble fraction was not a useful biomarker of reocclusion status. CONCLUSION: An association was found between MGP -7A>G and CD40 -1C>T polymorphisms, and reocclusion risk. The predictive scale that was generated permits the stratification of patients by their reocclusion risk with higher accuracy than clinical parameters alone.
机译:目的:在缺血性卒中急性期成功进行纤溶治疗后,发现重新闭塞的遗传预测因子。患者与方法:这是一项个案前瞻性研究,分析了在接受组织纤溶酶原激活剂治疗的222例患者中的236种多态性,其中16例患者发生了再阻塞事件(7.2%)。使用具有显性/隐性模型和串联闭塞的独立多态性,通过逻辑回归中的β系数加权,来生成预测量表。结果:使用显性/隐性模型,MGP基因的rs1800801 SNP(比值比[OR]:15.25; 95%CI:2.23-104.46;调整后的p = 0.006)和CD40基因的rs1883832 SNP(OR:0.077; 95%CI:0.009-0.66;调整后的p = 0.019)在通过临床预测因素进行逻辑回归调整后与再入院独立相关。在加性模型中,仅rs1883832 SNP(OR:4.43; 95%CI:1.62-12.15;调整后的p = 0.004)与重新闭塞的发生有关。生成的预测模型将再入院风险从不到1%分层到超过70%。如MGP -7A> G(AA:17.2%,AG + GG:AA),再闭塞与24 h神经功能恶化相关(再闭塞患者:26.7%,未闭塞患者:4.9%; p = 0.002)。 4.5%; p = 0.027),但对于CD40 1C> T则不是(CC:4.5%,CT + TT:7.7%; p = 0.565)。外周血单个核细胞中CD40 -1C> T基因型与CD40转录活性之间存在关联(中位表达值TT:65.75%,CT:70.80%,CC:96.​​00%; p = 0.023)。但是,CD40可溶性级分不是重新闭锁状态的有用的生物标志物。结论:MGP -7A> G和CD40 -1C> T多态性与再闭塞风险之间存在关联。所产生的预测量表允许患者通过其重新闭塞风险进行分层,其准确性高于单独的临床参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号